Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Shimon Slavin
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Procedures
Living Beings
Disorders
Chemicals & Drugs
Anatomy
Physiology
Sign-in to see full Profile
Network (preview)
114
Or, Reuven
88
Nagler, Arnon
83
Weiss, Lola
62
Naparstek, Elizabeth
50
Morecki, Shoshana
46
Ackerstein, Aliza
41
Shapira, Michael
33
Resnick, Igor
30
Samuel, Simcha
30
Aker, Memet
23
Kapelushnik, Joseph
22
Bitan, Menachem
22
Reich, Shoshana
21
Abdul-Hai, Ali
19
Gurevitch, Olga
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Shimon Slavin (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Kedmi Meirav; Resnick Igor B; Dray Liliane; Aker Memet; Samuel Simcha; Gesundheit Benjamin; Slavin Shimon; Or Reuven; Shapira Michael Y
A retrospective review of the outcome after second or subsequent allogeneic transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(4):483-9.
-
2009: Morecki Shoshana; Yacovlev Elena; Gelfand Yael; Shabat Yehudit; Slavin Shimon
Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2009;15(4):406-15.
-
2009: Har-Noy M; Zeira M; Weiss L; Fingerut E; Or R; Slavin S
Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.
Leukemia research 2009;33(4):525-38.
-
2009: Shapira M Y; Abdul-Hai A; Resnick I B; Bitan M; Tsirigotis P; Aker M; Gesundheit B; Slavin S; Or R
Alefacept treatment for refractory chronic extensive GVHD.
Bone marrow transplantation 2009;43(4):339-43.
-
2009: Gurevitch O; Slavin S; Resnick I; Khitrin S; Feldman A
Mesenchymal progenitor cells in red and yellow bone marrow.
Folia biologica 2009;55(1):27-34.
-
2008: Prigozhina Tatyana B; Elkin Gregory; Khitrin Sofia; Slavin Shimon
Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
Experimental hematology 2008;36(12):1750-9.
-
2008: Har-Noy M; Zeira M; Weiss L; Slavin S
Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity.
Leukemia research 2008;32(12):1903-13.
-
2008: Prigozhina Tatyana B; Khitrin Sofia; Elkin Gregory; Eizik Osnat; Morecki Shoshana; Slavin Shimon
Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation.
Experimental hematology 2008;36(10):1370-6.
-
2008: Morecki Shoshana; Gelfand Yael; Yacovlev Elena; Eizik Osnat; Shabat Yehudit; Slavin Shimon
CpG-induced myeloid CD11b+Gr-1+ cells efficiently suppress T cell-mediated immunoreactivity and graft-versus-host disease in a murine model of allogeneic cell therapy.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(9):973-84.
-
2008: Morecki Shoshana; Lindhofer Horst; Yacovlev Elena; Gelfand Yael; Ruf Peter; Slavin Shimon
Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.
Experimental hematology 2008;36(8):997-1003.
-
2008: Bitan Menachem; Weiss Lola; Zeira Michael; Reich Shoshana; Pappo Orit; Vlodavsky Israel; Slavin Shimon
Heparanase prevents the development of type 1 diabetes in non-obese diabetic mice by regulating T-cell activation and cytokines production.
Diabetes/metabolism research and reviews 2008;24(5):413-21.
-
2008: Resnick Igor B; Tsirigotis Panagiotis D; Shapira Michael Y; Aker Memet; Bitan Menachem; Samuel Simcha; Abdul-Hai Ali; Ackerstein Aliza; Or Reuven; Slavin Shimon
ABO incompatibility is associated with increased non-relapse and GVHD related mortality in patients with malignancies treated with a reduced intensity regimen: a single center experience of 221 patients.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(4):409-17.
-
2008: Weiss Lola; Botero-Anug Ana Maria; Hand Carla; Slavin Shimon; Naor David
CD44 gene vaccination for insulin-dependent diabetes mellitus in non-obese diabetic mice.
The Israel Medical Association journal : IMAJ 2008;10(1):20-5.
-
2008: Bitan M; Or R; Shapira M Y; Resnick I B; Gesundheit B; Ackerstein A; Samuel S; Elad S; Slavin S
Time to engraftment following allogeneic stem cell transplantation is significantly longer in patients with myelodysplastic syndrome than with acute myeloid leukemia.
Bone marrow transplantation 2008;41(1):69-78.
-
2008: Weiss Lola; Zeira Michael; Reich Shoshana; Slavin Shimon; Raz Itamar; Mechoulam Raphael; Gallily Ruth
Cannabidiol arrests onset of autoimmune diabetes in NOD mice.
Neuropharmacology 2008;54(1):244-9.
-
2008: Har-Noy M; Slavin S
The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?
Medical hypotheses 2008;70(6):1186-92.
-
2007: Tsirigotis P; Sella T; Shapira M Y; Bitan M; Bloom A; Kiselgoff D; Levin M; Libster D; Abdul Hai A; Gesundheit B; Or R; Slavin S; Resnick I
Peliosis hepatis following treatment with androgen-steroids in patients with bone marrow failure syndromes.
Haematologica 2007;92(11):e106-10.
-
2007: Resnick I B; Aker M; Tsirigotis P; Shapira M Y; Abdul-Hai A; Bitan M; Gesundheit B; Amar A; Ackerstein A; Samuel S; Slavin S; Or R
Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen.
Bone marrow transplantation 2007;40(10):957-64.
-
2007: Abdul-Hai A; Weiss L; Ergas D; Resnick I B; Slavin S; Shapira M Y
The effect of high-dose thiotepa, alone or in combination with other chemotherapeutic agents, on a murine B-cell leukemia model simulating autologous stem cell transplantation.
Bone marrow transplantation 2007;40(9):891-6.
-
2007: Abdul-Hai A; Weiss L; Ben-Yehuda A; Ergas D; Shapira M Y; Slavin S
Interleukin-7 induced facilitation of immunological reconstitution of sublethally irradiated mice following treatment with alloreactive spleen cells in a murine model of B-cell leukemia/lymphoma (BCL1).
Bone marrow transplantation 2007;40(9):881-9.
-
2007: Amer Johnny; Weiss Lola; Reich Shoshana; Shapira Michael Y; Slavin Shimon; Fibach Eitan
The oxidative status of blood cells in a murine model of graft-versus-host disease.
Annals of hematology 2007;86(10):753-8.
-
2007: Shapira Michael Y; Tsirigotis P; Resnick I B; Or R; Abdul-Hai A; Slavin S
Allogeneic hematopoietic stem cell transplantation in the elderly.
Critical reviews in oncology/hematology 2007;64(1):49-63.
-
2007: Naor David; Nedvetzki Shlomo; Walmsley Marita; Yayon Avner; Turley Eva A; Golan Ira; Caspi Dan; Sebban Lora Eshkar; Zick Yehiel; Garin Tali; Karussis Dimitrios; Assayag-Asherie Nathalie; Raz Itamar; Weiss Lola; Slavin Shimon; Golan Itshak
CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice.
Annals of the New York Academy of Sciences 2007;1110():233-47.
-
2007: Morecki Shoshana; Yacovlev Elena; Gelfand Yael; Eizik Osnat; Slavin Shimon
Pretransplant treatment of donors with immunomodulators to control graft-versus-host disease (GVHD) in transplant recipients.
Experimental hematology 2007;35(5):748-56.
-
2007: Prigozhina T B; Elkin G; Slavin S
Deletion of donor-reactive cells as a new conditioning regimen for allogeneic bone marrow transplantation.
Transplantation proceedings 2007;39(3):678-84.
-
2007: Weiss Lola; Reich Shoshana; Zeira Michael; Or Reuven; Resnick Igor B; Slavin Shimon; Shapira Michael Y
N-acetylcysteine mildly inhibits the graft-vs.-leukemia effect but not the lymphokine activated cells (LAK) activity.
Transplant immunology 2007;17(3):198-202.
-
2007: Gurevitch Olga; Khitrin Sofia; Valitov Andrei; Slavin Shimon
Osteoporosis of hematologic etiology.
Experimental hematology 2007;35(1):128-36.
-
2007: Shapira Michael Y; Hai Ali Abdul; Tsirigotis Panagiotis; Resnick Igor B; Or Reuven; Slavin Shimon
Hematopoietic stem cell therapy for malignant diseases.
Annals of medicine 2007;39(6):465-73.
-
2007: Gurevitch Olga; Slavin Shimon; Feldman Anatol G
Conversion of red bone marrow into yellow - Cause and mechanisms.
Medical hypotheses 2007;69(3):531-6.
-
2006: Or R; Hadar E; Bitan M; Resnick I B; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira M Y
Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(12):1295-301.
-
2006: Abdul-Hai Ali; Ben-Yehuda Arie; Galsky Haya; Slavin Shimon; Or Reuven
Interleukin 2 regulation following semi-allogeneic bone marrow transplantation in mice.
Cancer immunology, immunotherapy : CII 2006;55(11):1330-6.
-
2006: Miodosky M; Abdul-Hai A; Tsirigotis P; Or R; Bitan M; Resnick I B; Gesundheit B; Zilberman I; Ioffe L; Leubovic A; Slavin S; Shapira M Y
Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate.
Bone marrow transplantation 2006;38(7):507-11.
-
2006: Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira M Y
Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
Bone marrow transplantation 2006;38(5):359-64.
-
2006: Bitan M; Or R; Shapira M Y; Aker M; Resnick I B; Ackerstein A; Samuel S; Elad S; Slavin S
Fludarabine-based reduced intensity conditioning for stem cell transplantation of Fanconi anemia patients from fully matched related and unrelated donors.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(7):712-8.
-
2006: Tsirigotis Panagiotis; Bitan Reuven OrMenachem; Resnick Igor B; Samuel Simcha; Ackerstein Aliza; Eladì Sharon; Gesundheit Benjamin; Zilberman Irina; Miron Svetlana; Leubovic Alexander; Slavin Shimon; Shapira Michael Y
A non-myeloablative conditioning regimen in allogeneic stem cell transplantation from related and unrelated donors in elderly patients.
Haematologica 2006;91(6):852-5.
-
2006: Gross David J; Munter Gabriel; Bitan Menachem; Siegal Tali; Gabizon Alberto; Weitzen Ronny; Merimsky Ofer; Ackerstein Aliza; Salmon Asher; Sella Avishai; Slavin Shimon;
The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.
Endocrine-related cancer 2006;13(2):535-40.
-
2006: Resnick Igor B; Aker Memet; Shapira Michael Y; Tsirigotis Panagiotis D; Bitan Menachem; Abdul-Hai Ali; Samuel Simcha; Ackerstein Aliza; Gesundheit Benjamin; Zilberman Irina; Miron Svetlana; Yoffe Luba; Lvovich Alex; Slavin Shimon; Or Reuven
Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.
British journal of haematology 2006;133(6):649-54.
-
2006: Shapira Michael Y; Resnick Igor B; Tsirigotis Panagiotis D; Slavin Shimon
Biological response modifiers as adjuncts to stem cell transplantation.
Expert opinion on biological therapy 2006;6(5):467-83.
-
2006: Abdul-Hai Ali; Weiss Lola; Slavin Shimon; Or Reuven
Improved survival following induction of GVHD following lipopolysaccharide immunization.
Experimental hematology 2006;34(4):549-53.
-
2006: Weiss L; Zeira M; Reich S; Har-Noy M; Mechoulam R; Slavin S; Gallily R
Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.
Autoimmunity 2006;39(2):143-51.
-
2006: Karussis Dimitrios; Grigoriadis Savas; Polyzoidou Eleni; Grigoriadis Nikolaos; Slavin Shimon; Abramsky Oded
Neuroprotection in multiple sclerosis.
Clinical neurology and neurosurgery 2006;108(3):250-4.
-
2006: Morecki Shoshana; Lindhofer Horst; Yacovlev Elena; Gelfand Yael; Slavin Shimon
Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes.
Blood 2006;107(4):1564-9.
-
2006: Gurevitch Olga; Slavin Shimon
The hematological etiology of osteoporosis.
Medical hypotheses 2006;67(4):729-35.
-
2005: Resnick Igor B; Abdul Hai Ali; Shapira Michael Y; Bitan Menachem; Hershkovitz Eli; Schwartz Arie; Ben-Harush Miriam; Or Reuven; Slavin Shimon; Kapelushnik Joseph
Treatment of X-linked childhood cerebral adrenoleukodystrophy by the use of an allogeneic stem cell transplantation with reduced intensity conditioning regimen.
Clinical transplantation 2005;19(6):840-7.
-
2005: Shapira M Y; Resnick I B; Bitan M; Ackerstein A; Tsirigotis P; Gesundheit B; Zilberman I; Miron S; Leubovic A; Slavin S; Or R
Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report.
Bone marrow transplantation 2005;36(12):1097-101.
-
2005: Yang Iris; Weiss Lola; Abdul-Hai Ali; Kasir Judith; Reich Shoshana; Slavin Shimon
Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
Cancer research 2005;65(21):9735-40.
-
2005: Bitan Menachem; Or Reuven; Shapira Michael Y; Resnick Igor B; Ackerstein Aliza; Samuel Simcha; Elad Sharon; Slavin Shimon
Successful engraftment following allogeneic stem cell transplantation in very high-risk patients with busulfan as a single agent.
Haematologica 2005;90(8):1089-95.
-
2005: Resnick I B; Shapira M Y; Slavin S
Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Transplant immunology 2005;14(3-4):207-19.
-
2005: Bitan Menachem; Shapira Michael Y; Resnick Igor B; Zilberman Irina; Miron Svetlana; Samuel Simcha; Ackerstein Aliza; Elad Sharon; Israel Shosh; Amar Avraham; Fibach Eitan; Or Reuven; Slavin Shimon
Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+-purified stem cells.
Experimental hematology 2005;33(6):713-8.
-
2005: De Santis D; Bishara A; Witt C S; Nagler A; Brautbar C; Slavin S; Christiansen F T
Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants.
Tissue antigens 2005;65(6):519-28.
-
2005: Bitan M; Or R; Shapira M Y; Ackerstein A; Samuel S; Slavin S
Nonmyeloablative stem cell transplantation using lymphoablative rather than myeloablative conditioning in the prefludarabine era by ATG and limiting doses of cyclophosphamide.
Bone marrow transplantation 2005;35(10):953-8.
-
2005: Shapira Michael Y; Hirshfeld Ester; Weiss Lola; Zeira Michael; Kasir Judith; Or Reuven; Resnick Igor B; Slavin Shimon
Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model.
Cancer immunology, immunotherapy : CII 2005;54(4):383-8.
-
2005: Abdul-Hai A; Hershkoviz R; Weiss L; Lider O; Slavin S
Effect of Linomide on adhesion molecules, TNF-alpha, nitrogen oxide, and cell adhesion.
International immunopharmacology 2005;5(2):231-9.
-
2005: Slavin Shimon
Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation.
Acta haematologica 2005;114(4):214-20.
-
2004: Resnick Igor B; Gomori John M; Kiselgoff David; Lossos Alex; Zilberman Irina; Miron Svetlana; Bitan Menachem; Or Reuven; Slavin Shimon; Shapira Michael Y
Spinal epidural lipomatosis following haploidentical allogeneic bone marrow transplantation for non-Hodgkin lymphoma.
Clinical transplantation 2004;18(6):762-5.
-
2004: Or Reuven; Aker Memet; Shapira Michael Yechiel; Resnick Igor; Bitan Menachem; Samuel Simcha; Slavin Shimon
Allogeneic stem cell transplantation for the treatment of diseases associated with a deficiency in bone marrow products.
Springer seminars in immunopathology 2004;26(1-2):133-42.
-
2004: Prigozhina Tatyana B; Elkin Gregory; Khitrin Sofia; Slavin Shimon
Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.
Experimental hematology 2004;32(11):1110-7.
-
2004: Prigozhina Tatyana B; Elkin Gregory; Gurevitch Olga; Morecki Shoshana; Yakovlev Elena; Khitrin Sofia; Slavin Shimon
Depletion of alloantigen-primed lymphocytes overcomes resistance to allogeneic bone marrow in mildly conditioned recipients.
Blood cells, molecules & diseases 2004;33(3):238-47.
-
2004: Prigozhina Tatyana; Slavin Shimon
Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts.
Springer seminars in immunopathology 2004;26(1-2):169-85.
-
2004: Slavin Shimon
Reduced intensity versus truly nonmyeloablative conditioning for stem-cell transplant recipients.
Transplantation 2004;78(7):964-5.
-
2004: Bitan Menachem; Or Reuven; Shapira Michael Y; Mador Nurith; Resnick Igor B; Saleh Niveen; Weinberger Klaus M; Samuel Simcha; Schechter Esther; Slavin Shimon; Wolf Dana G
Early-onset Guillain-Barré syndrome associated with reactivation of Epstein-Barr virus infection after nonmyeloablative stem cell transplantation.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(7):1076-8.
-
2004: Panigrahi Soumya; Morecki Shoshana; Yacovlev Elena; Gelfand Yael; Kassir Judith; Slavin Shimon
A novel approach for prevention of lethal GVHD by selective elimination of alloreactive donor lymphocytes prior to stem cell transplantation.
Experimental hematology 2004;32(8):756-64.
-
2004: Karussis Dimitrios; Slavin Shimon
Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
Journal of the neurological sciences 2004;223(1):59-64.
-
2004: Slavin Shimon
Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation.
Lancet 2004;364(9429):122-4.
-
2004: Morecki Shoshana; Panigrahi Soumya; Pizov Galina; Yacovlev Elena; Gelfand Yael; Eizik Osnat; Slavin Shimon
Effect of KRN7000 on induced graft-vs-host disease.
Experimental hematology 2004;32(7):630-7.
-
2004: Shapira M Y; Resnick I B; Bitan M; Ackerstein A; Samuel S; Elad S; Miron S; Zilberman I; Slavin S; Or R
Low transplant-related mortality with allogeneic stem cell transplantation in elderly patients.
Bone marrow transplantation 2004;34(2):155-9.
-
2004: Elkin Gregory; Prigozhina Tatyana B; Slavin Shimon
Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.
Experimental hematology 2004;32(6):579-84.
-
2004: Weiss L; Reich S; Mandelboim O; Slavin S
Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy.
Bone marrow transplantation 2004;33(11):1137-41.
-
2004: Weiss Lola; Or Reuven; Slavin Shimon; Naparstek Ella; Reich Shoshana; Abdul-Hai Ali
Immunotherapy of murine leukemia following non-myeloablative conditioning with naïve or G-CSF mobilized blood or bone marrow stem cells.
Cancer immunology, immunotherapy : CII 2004;53(4):358-62.
-
2004: Bloom Allan I; Shapira Michael Y; Or Reuven; Sasson Talia; Resnick Igor B; Zilberman Irena; Verstandig Anthony; Aker Memet; Slavin Shimon; Muszkat Mordechai
Intrahepatic arterial administration of low-dose methotrexate in patients with severe hepatic graft-versus-host disease: an open-label, uncontrolled trial.
Clinical therapeutics 2004;26(3):407-14.
-
2004: Kipnis Jonathan; Avidan Hila; Markovich Yifat; Mizrahi Tal; Hauben Ehud; Prigozhina Tatyana B; Slavin Shimon; Schwartz Michal
Low-dose gamma-irradiation promotes survival of injured neurons in the central nervous system via homeostasis-driven proliferation of T cells.
The European journal of neuroscience 2004;19(5):1191-8.
-
2004: Bishara A; De Santis D; Witt C C; Brautbar C; Christiansen F T; Or R; Nagler A; Slavin S
The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
Tissue antigens 2004;63(3):204-11.
-
2004: Slavin Shimon; Morecki Shoshana; Weiss Lola; Shapira Michael Y; Resnick Igor; Or Reuven
Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside.
Seminars in oncology 2004;31(1):4-21.
-
2004: Slavin Shimon
Reduced-intensity conditioning or nonmyeloablative stem cell transplantation: introduction, rationale, and historic background.
Seminars in oncology 2004;31(1):1-3.
-
2004: Morecki Shoshana; Yacovlev Elena; Gelfand Yael; Vilensky Anna; Slavin Shimon
Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2004;10(1):40-8.
-
2003: Bitan M; Resnick I B; Or R; Rokach A; Laxer U; Ackerstein A; Elad S; Slavin S; Shapira M Y
Rhinolalia as a presenting sign of pneumomediastinum complicating post peripheral blood stem cell transplantation bronchiolitis obliterans.
American journal of hematology 2003;74(3):182-6.
-
2003: Slavin Shimon
Graft-versus-host disease, the graft-versus-leukemia effect, and mixed chimerism following nonmyeloablative stem cell transplantation.
International journal of hematology 2003;78(3):195-207.
-
2003: Gross David J; Reibstein Israel; Weiss Lola; Slavin Shimon; Dafni Hagit; Neeman Michal; Pines Mark; Nagler Arnon
Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3788-93.
-
2003: Shapira M Y; Or R; Resnick I B; Bitan M; Ackerstein A; Samuel S; Elad S; Zilberman I; Miron S; Slavin S
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
Bone marrow transplantation 2003;32(6):557-61.
-
2003: Ji Y H; Weiss L; Zeira M; Abdul-Hai A; Reich S; Schuger L; Slavin S
Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses.
Bone marrow transplantation 2003;32(5):495-504.
-
2003: Slavin Shimon; Morecki Shoshana; Weiss Lola; Or Reuven
Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man.
Critical reviews in oncology/hematology 2003;46(2):139-63.
-
2003: Prigozhina Tatyana B; Gurevitch Olga; Elkin Gregory; Morecki Shoshana; Yakovlev Elena; Slavin Shimon
CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells.
Experimental hematology 2003;31(1):81-8.
-
2003: Or Reuven; Shapira Michael Y; Resnick Igor; Amar Avraham; Ackerstein Aliza; Samuel Simcha; Aker Memet; Naparstek Elizabeth; Nagler Arnon; Slavin Shimon
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.
Blood 2003;101(2):441-5.
-
2003: Patinkin Deborah; Hidmi Adel; Weiss Lola; Slavin Shimon; Katzhendler Joshua
The effect of pegylated antisense acetylcholinesterase on hematopoiesis.
Oligonucleotides 2003;13(4):207-16.
-
2003: Gurevitch Olga; Kurkalli Basan Gowda S; Prigozhina Tatyana; Kasir Judith; Gaft Anna; Slavin Shimon
Reconstruction of cartilage, bone, and hematopoietic microenvironment with demineralized bone matrix and bone marrow cells.
Stem cells (Dayton, Ohio) 2003;21(5):588-97.
-
2003: Panigrahi Soumya; Das Mayukh; Stagler Dalia; Konstantini Shlomi; Gmori Moshe; Slavin Shimon; Nagler Arnon
Development of secondary anaplastic oligoastrocytoma after matched unrelated bone marrow transplantation in a child with acute myeloid leukemia.
Acta haematologica 2003;109(4):196-8.
-
2002: Slavin S
Non-myeloablative stem cell transplantation for induction of host-versus-graft tolerance for adoptive immunotherapy of malignant and nonmalignant diseases and towards transplantation of organ allografts.
Transplantation proceedings 2002;34(8):3371-3.
-
2002: Weiss Lola; Abdul-Hai Ali; Shufaro Yoel; Reich Shoshanna; Slavin Shimon
Linomide administration following bone marrow transplantation in mice.
Cancer immunology, immunotherapy : CII 2002;51(11-12):596-602.
-
2002: Shapira Michael Y; Bloom Allan I; Or Reuven; Sasson Talia; Nagler Arnon; Resnick Igor B; Aker Memet; Zilberman Irina; Slavin Shimon; Verstanding Anthony
Intra-arterial catheter directed therapy for severe graft-versus-host disease.
British journal of haematology 2002;119(3):760-4.
-
2002: Slavin Shimon; Aker Mehmet; Shapira Michael Y; Panigrahi Soumya; Gabriel Cividalli; Or Reuven
Non-myeloablative stem cell transplantation for the treatment of cancer and life-threatening non-malignant disorders; past accomplishments and future goals.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2002;27(2):159-66.
-
2002: Slavin Shimon
Maternal-fetal relationship, natural chimerism and bilateral transplantation tolerance as the basis for non-myeloablative stem cell transplantation.
International journal of hematology 2002;76 Suppl 1():172-5.
-
2002: Gurevich Olga; Vexler Akiva; Marx Gerard; Prigozhina Tatyana; Levdansky Lila; Slavin Shimon; Shimeliovich Irina; Gorodetsky Raphael
Fibrin microbeads for isolating and growing bone marrow-derived progenitor cells capable of forming bone tissue.
Tissue engineering 2002;8(4):661-72.
-
2002: Weiss Lola; Barak Vivian; Zeira Michael; Abdul-Hai Ali; Raibstein Israel; Reich Shoshana; Hirschfeld Esther; Gross David; Slavin Shimon
Cytokine production in Linomide-treated nod mice and the potential role of a Th (1)/Th(2) shift on autoimmune and anti-inflammatory processes.
Cytokine 2002;19(2):85-93.
-
2002: Elkin G; Prighozina T B; Gurevitch O; Slavin S
Nonmyeloablative bone marrow transplantation based on deletion of host-anti-donor alloreactive cells prevents autoimmune insulitis and diabetes in nonobese diabetic mice.
Transplantation proceedings 2002;34(4):1303-6.
-
2002: Slavin Shimon; Morecki Shoshana; Weiss Lola; Or Reuven
Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Journal of hematotherapy & stem cell research 2002;11(2):265-76.
-
2002: Slavin Shimon; Nagler Arnon; Shapira Michael Y; Aker Mehmet; Gabriel Cividalli; Or Reuven
Treatment of leukemia by alloreactive lymphocytes and nonmyeloablative stem cell transplantation.
Journal of clinical immunology 2002;22(2):64-9.
-
2002: Prigozhina Tatyana B; Gurevitch Olga; Morecki Shoshana; Yakovlev Elena; Elkin Gregory; Slavin Shimon
Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models.
Experimental hematology 2002;30(1):89-96.
-
2002: Panigrahi Soumya; Yacovlev Elena; Gelfand Yael; Schuger Lucia; Slavin Shimon; Morecki Shoshana
Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer.
Cytokines, cellular & molecular therapy 2002;7(3):99-106.
-
2002: Slavin Shimon
Donor lymphocyte infusions for hematopoietic malignancy.
Cancer chemotherapy and biological response modifiers 2002;20():291-9.
-
2001: Slavin S; Ackerstein A; Morecki S; Gelfand Y; Cividalli G
Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes.
Bone marrow transplantation 2001;28(8):795-8.
-
2001: Slavin S
Immunotherapy of cancer with alloreactive lymphocytes.
The lancet oncology 2001;2(8):491-8.
-
2001: Slavin S; Or R; Aker M; Shapira M Y; Panigrahi S; Symeonidis A; Cividalli G; Nagler A
Nonmyeloablative stem cell transplantation for the treatment of cancer and life-threatening nonmalignant disorders: past accomplishments and future goals.
Cancer chemotherapy and pharmacology 2001;48 Suppl 1():S79-84.
-
2001: Morecki S; Gelfand Y; Nagler A; Or R; Naparstek E; Varadi G; Engelhard D; Akerstein A; Slavin S
Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen.
Bone marrow transplantation 2001;28(3):243-9.
-
2001: Slavin S; Nagler A; Shapira M; Panigrahi S; Samuel S; Or A
Non-myeloablative allogeneic stem cell transplantation focusing on immunotherapy of life-threatening malignant and non-malignant diseases.
Critical reviews in oncology/hematology 2001;39(1-2):25-9.
-
2001: Slavin S; Nagler A; Aker M; Shapira M Y; Cividalli G; Or R
Non-myeloablative stem cell transplantation and donor lymphocyte infusion for the treatment of cancer and life-threatening non-malignant disorders.
Reviews in clinical and experimental hematology 2001;5(2):135-46.
-
2001: Gross D J; Weiss L; Reibstein I; Hedlund G; Dahlén E; Rapoport M J; Slavin S
The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus.
International immunopharmacology 2001;1(6):1131-9.
-
2001: Panigrahi S; Nagler A; Or R; Wolf D G; Slavin S; Shapira M Y
Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.
Bone marrow transplantation 2001;27(6):659-61.
-
2001: Nagler A; Aker M; Or R; Naparstek E; Varadi G; Brautbar C; Slavin S
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation.
Experimental hematology 2001;29(3):362-70.
-
2001: Morecki S; Yacovlev E; Gelfand Y; Uzi I; Slavin S
Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(2):114-21.
-
2000: Nagler A; Ackerstein A; Or R; Naparstek E; Slavin S
Adoptive immunotherapy with haploidentical allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation.
Experimental hematology 2000;28(11):1225-31.
-
2000: Slavin S
New strategies for bone marrow transplantation.
Current opinion in immunology 2000;12(5):542-51.
-
2000: Ilan Y; Nagler A; Zeira E; Adler R; Slavin S; Shouval D
Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients.
Bone marrow transplantation 2000;26(6):633-8.
-
2000: Nagler A; Or R; Naparstek E; Varadi G; Slavin S
Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.
Experimental hematology 2000;28(9):1096-104.
-
2000: Slavin S; Nagler A; Varadi G; Or R
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
Experimental hematology 2000;28(7):853-7.
-
2000: Morecki S; Slavin S
Toward amplification of a graft-versus-leukemia effect while minimizing graft-versus-host disease.
Journal of hematotherapy & stem cell research 2000;9(3):355-66.
-
2000: Slavin S; Or R; Prighozina T; Gurevitch O; Aker M; Panighari S; Shapira M; Nagler A
Immunotherapy of hematologic malignancies and metastatic solid tumors in experimental animals and man.
Bone marrow transplantation 2000;25 Suppl 2():S54-7.
-
2000: Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
Bone marrow transplantation 2000;25(10):1021-8.
-
2000: Morecki S; Yacovlev E; Gelfand Y; Trembovler V; Shohami E; Slavin S
Induction of antitumor immunity by indomethacin.
Cancer immunology, immunotherapy : CII 2000;48(11):613-20.
-
2000: Weiss L; Slavin S; Reich S; Cohen P; Shuster S; Stern R; Kaganovsky E; Okon E; Rubinstein A M; Naor D
Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(1):285-90.
-
1999: Gross D J; Reibstein I; Weiss L; Slavin S; Stein I; Neeman M; Abramovitch R; Benjamin L E
The antiangiogenic agent linomide inhibits the growth rate of von Hippel-Lindau paraganglioma xenografts to mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3669-75.
-
1999: Gurevitch O; Prigozhina T B; Pugatsch T; Slavin S
Transplantation of allogeneic or xenogeneic bone marrow within the donor stromal microenvironment.
Transplantation 1999;68(9):1362-8.
-
1999: Rosales F; Naparstek E; Varadi G; Or R; Slavin S; Nagler A
The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia.
Leukemia research 1999;23(10):947-52.
-
1999: Prigozhina T B; Gurevitch O; Slavin S
Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice.
Experimental hematology 1999;27(10):1503-10.
-
1999: Weiss L; Reich S; Slavin S
Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Cytokines, cellular & molecular therapy 1999;5(3):153-8.
-
1999: Weiss L; Reich S; Slavin S
Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Cytokines, cellular & molecular therapy 1999;5(3):145-52.
-
1999: Nagler A; Ackerstein A; Kapelushnik J; Or R; Naparstek E; Slavin S
Donor lymphocyte infusion post-non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease.
Bone marrow transplantation 1999;24(3):339-42.
-
1999: Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
Experimental hematology 1999;27(7):1210-8.
-
1999: Mumcuoglu M; Slavin S
Enhancement of hematopoietic reconstitution with recombinant cytokines: effect of rhIL-6 in combination with rhGM-CSF and rhIL-3 on unmodified or T cell-depleted bone marrow.
Journal of hematotherapy 1999;8(3):247-53.
-
1999: Weiss L; Slavin S
Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin.
Bone marrow transplantation 1999;23(11):1139-43.
-
1999: Varadi G; Or R; Kapelushnik J; Naparstek E; Nagler A; Brautbar C; Amar A; Kirschbaum M; Samuel S; Slavin S; Siegal T
Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma.
Leukemia & lymphoma 1999;34(1-2):185-90.
-
1999: Aker M; Varadi G; Slavin S; Nagler A
Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 1999;21(3):237-9.
-
1999: Rosales F; Peylan-Ramu N; Cividalli G; Varadi G; Or R; Naparstek E; Slavin S; Nagler A
The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Bone marrow transplantation 1999;23(9):861-5.
-
1999: Nagler A; Morecki S; Slavin S
The use of soybean agglutinin (SBA) for bone marrow (BM) purging and hematopoietic progenitor cell enrichment in clinical bone-marrow transplantation.
Molecular biotechnology 1999;11(2):181-94.
-
1999: Ben-Yehuda A; Wirtheim E; Abdul-Hai A; Or R; Slavin S; Babaey S; Friedman G
Activation of the recombination activating gene 1 (RAG-1) transcript in bone marrow of senescent C57BL/6 mice by recombinant interleukin-7.
The journals of gerontology. Series A, Biological sciences and medical sciences 1999;54(4):B143-8.
-
1999: Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Experimental hematology 1999;27(3):461-9.
-
1999: Slavin S; Prighozina T; Gurevitch O; Zhu J; Gross D; Rabstein I; Weiss L
New approaches for control of anti-self reactivity in type 1 diabetes mellitus and transplantation of pancreatic islets.
Journal of molecular medicine (Berlin, Germany) 1999;77(1):223-5.
-
1998: Slavin S; Gurevitch O; Prighozina T
Induction of bilateral transplantation tolerance to cellular and perfused allografts and xenografts with donor hematopoietic cells.
Annals of the New York Academy of Sciences 1998;862():37-44.
-
1998: Slavin S; Gurevitch O; Zhu J; Prighozina T
Deletion of donor-reactive cells followed by stem cell transplantation in recipients treated with total lymphoid-irradiation as a means for induction of transplantation tolerance to organ allografts and xenografts.
Transplantation proceedings 1998;30(8):4021-2.
-
1998: Or R; Ackerstein A; Nagler A; Amar A; Naparstek E; Varadi G; Kapelushnik J; Samuel S; Pugatsch T; Brautbar C; Slavin S
Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1998;21(6):447-53.
-
1998: Nagler A; Finlander R; Or R; Naparstek E; Varadi G; Slavin S
The role of thiotepa in autologous bone marrow transplantation for acute leukemia.
Leukemia research 1998;22(11):991-5.
-
1998: Morecki S; Yacovlev E; Diab A; Slavin S
Allogeneic cell therapy for a murine mammary carcinoma.
Cancer research 1998;58(17):3891-5.
-
1998: Morecki S; Nagler A; Zakay-Rones Z; Schlesinger M; Lubina-Salomon A; Pugatsch T; Moshel Y; Slavin S
Tumorigenicity and immunogenicity in a murine model of B-cell leukemia/lymphoma (BCL1).
Leukemia research 1998;22(9):831-5.
-
1998: Nagler A; Condiotti R; Nabet C; Naparstek E; Or R; Samuel S; Slavin S
Selective CD4+ T-cell depletion does not prevent graft-versus-host disease.
Transplantation 1998;66(1):138-41.
-
1998: Bishara A; Aker M; Amar A; Brautbar C; Schlesinger M; Rabinowitz R; Slavin S; Baniyash M
Enhanced lymphoid cell recovery after bone marrow transplantation: correlation with the presence of costimulatory antibodies in serum.
Experimental hematology 1998;26(7):580-7.
-
1998: Morecki S; Lubina-Salomon A; Slavin S; Nagler A
Cytokine gene transduction into non-immunogeneic murine tumor cells.
Cytokines, cellular & molecular therapy 1998;4(2):87-94.
-
1998: Gross D J; Weiss L; Reibstein I; van den Brand J; Okamoto H; Clark A; Slavin S
Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment.
Endocrinology 1998;139(5):2369-74.
-
1998: Kapelushnik J; Aker M; Pugatsch T; Samuel S; Slavin S
Bone marrow transplantation from a cadaveric donor.
Bone marrow transplantation 1998;21(8):857-8.
-
1998: Or R; Ackerstein A; Nagler A; Kapelushnik J; Naparstek E; Samuel S; Amar A; Bruatbar C; Slavin S
Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study.
Cytokines, cellular & molecular therapy 1998;4(1):1-6.
-
1998: Aker M; Kapelushnik J; Pugatsch T; Naparstek E; Ben-Neria S; Yehuda O; Amar A; Nagler A; Slavin S; Or R
Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major.
Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology 1998;20(2):145-8.
-
1998: Morecki S; Yacovlev L; Slavin S
Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma.
International journal of cancer. Journal international du cancer 1998;75(6):894-9.
-
1998: Slavin S; Nagler A; Naparstek E; Kapelushnik Y; Aker M; Cividalli G; Varadi G; Kirschbaum M; Ackerstein A; Samuel S; Amar A; Brautbar C; Ben-Tal O; Eldor A; Or R
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Blood 1998;91(3):756-63.
-
1998: Nagler A; Ackerstein A; Ben-Shahar M; Or R; Naparstek E; Ben-Yosef R; Slavin S
Continuous interleukin-2 infusion combined with cyclophosphamide- based combination chemotherapy in the treatment of hemato-oncological malignancies. Results of a phase I-II study.
Acta haematologica 1998;100(2):63-8.
-
1998: Slavin S; Nagler A
Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9 Suppl 1():S31-9.
-
1997: Kapelushnik J; Or R; Slavin S; Nagler A
A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia.
Bone marrow transplantation 1997;20(12):1109-10.
-
1997: Slavin S; Nagler A
Cytokine-mediated immunotherapy following autologous bone marrow transplantation in lymphoma and evidence of interleukin-2-induced immunomodulation in allogeneic transplants.
The cancer journal from Scientific American 1997;3 Suppl 1():S59-67.
-
1997: Prigozhina T B; Gurevitch O; Zhu J; Slavin S
Induction of mixed hematopoietic chimerism and specific transplantation tolerance to allogeneic and xenogeneic grafts by selective elimination of donor-reactive host cells following nonmyeloablative conditioning.
Transplantation proceedings 1997;29(6):2644-6.
-
1997: Ben-Yosef R; Or R; Naparstek E; Kapelushnik J; Samuels S; Slavin S; Nagler A
Should soybean agglutinin purging be performed in breast cancer patients undergoing autologous stem cell transplantation? A retrospective analysis of 48 patients.
American journal of clinical oncology 1997;20(4):419-23.
-
1997: Slavin S; Weiss L; Prighozina T; Gurevitch O; Zhu J; Rabstein I; Gross D
New approaches for control of anti-self-reactivity in type 1 diabetes and transplantation of pancreatic islets.
Transplantation proceedings 1997;29(4):1929-31.
-
1997: Nagler A; Ackerstein A; Or R; Naparstek E; Slavin S
Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation.
Blood 1997;89(11):3951-9.
-
1997: Shapira-Nahor O; Marcus H; Segall H; Lubin I; Slavin S; Panet A; Reisner Y
Human T cells recovered from human/Balb radiation chimeras are hypersensitive to human immunodeficiency virus type 1 infection.
Journal of virology 1997;71(6):4495-501.
-
1997: Prigozhina T B; Gurevitch O; Zhu J; Slavin S
Permanent and specific transplantation tolerance induced by a nonmyeloablative treatment to a wide variety of allogeneic tissues: I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes.
Transplantation 1997;63(10):1394-9.
-
1997: Morecki S; Gelfand Y; Levi S; Nagler A; Condiotti R; Nabet C; Ackerstein A; Slavin S
Activated long-term peripheral blood cultures as preparation for adoptive alloreactive cell therapy in cancer patients.
Journal of hematotherapy 1997;6(2):115-24.
-
1997: Morecki S; Moshel Y; Gelfend Y; Pugatsch T; Slavin S
Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma.
International journal of cancer. Journal international du cancer 1997;71(1):59-63.
-
1997: Abdul-Hai A; Ben-Yehuda A; Weiss L; Friedman G; Zakay-Rones Z; Slavin S; Or R
Interleukin-7-enhanced cytotoxic T lymphocyte activity after viral infection in marrow transplanted mice.
Bone marrow transplantation 1997;19(6):539-43.
-
1997: Morecki S; Nabet C; Falk P; Fridkis-Hareli M; Pecht I; Mond J J; Slavin S
The effect of linomide, an immunoregulator in experimental autoimmune diseases, on humoral antibody responses in mice.
Autoimmunity 1997;25(4):223-32.
-
1996: Gurevitch O; Slavin S; Muhlrad A; Shteyer A; Gazit D; Chorev M; Vidson M; Namdar-Attar M; Berger E; Bleiberg I; Bab I
Osteogenic growth peptide increases blood and bone marrow cellularity and enhances engraftment of bone marrow transplants in mice.
Blood 1996;88(12):4719-24.
-
1996: Kapelushnik J; Nagler A; Or R; Naparstek E; Ackerstein A; Samuel S; Morecki S; Nabet C; Slavin S
Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.
Bone marrow transplantation 1996;18(6):1153-6.
-
1996: Slavin S
Immunoregulation rather than immunosuppression for prevention and treatment of autoimmune disorders.
Transplantation proceedings 1996;28(6):3021-2.
-
1996: Singhal S; Vourka-Karussis U; Mehta J; Slavin S; Weiss L
Failure of cyclosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice.
Leukemia research 1996;20(11-12):941-6.
-
1996: Slavin S; Weiss L; Xia W; Gross D J
Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide).
Cell transplantation 1996;5(6):627-30.
-
1996: Mumcuoglu M; Zakay-Rones Z; Weiss L; Slavin S
Enhancement of primary and secondary responses to sheep red blood cells and influenza virus in BALB/c mice by recombinant human interleukin-2.
Experimental hematology 1996;24(13):1516-20.
-
1996: Nagler A; Brautbar C; Slavin S; Bishara A
Bone marrow transplantation using unrelated and family related donors: the impact of HLA-C disparity.
Bone marrow transplantation 1996;18(5):891-7.
-
1996: Weiss L; Nusair S; Reich S; Sidi H; Slavin S
Induction of graft versus leukemia effects by cell-mediated lymphokine-activated immunotherapy after syngeneic bone marrow transplantation in murine B cell leukemia.
Cancer immunology, immunotherapy : CII 1996;43(2):103-8.
-
1996: Arad G; Katzenellenbogen M; Levy R; Slavin S; Kaempfer R
Linomide, an immunomodulator that inhibits Th1 cytokine gene expression.
International immunology 1996;8(10):1603-7.
-
1996: Abdul-Hai A; Or R; Slavin S; Friedman G; Weiss L; Matsa D; Ben-Yehuda A
Stimulation of immune reconstitution by interleukin-7 after syngeneic bone marrow transplantation in mice.
Experimental hematology 1996;24(12):1416-22.
-
1996: Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
Bone marrow transplantation 1996;18(4):721-4.
-
1996: Kapelushnik J; Naparstek E; Nagler A; Filon D; Oppenheim A; Amar A; Aker M; Samuel S; Slavin S
Second transplantation using allogeneic peripheral blood stem cells in a beta-thalassaemia major patient featuring stable mixed chimaerism.
British journal of haematology 1996;94(2):285-7.
-
1996: Toren A; Novick D; Or R; Ackerstein A; Slavin S; Nagler A
Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.
Transplantation 1996;62(1):138-42.
-
1996: Weiss L; Reich S; Slavin S
Effect of deoxyspergualin on graft-versus-host disease and graft- versus-leukemia in mice.
Bone marrow transplantation 1996;17(5):789-92.
-
1996: Slavin S; Naparstek E; Nagler A; Kapelushnik Y; Ackerstein A; Or R
Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT.
Blood 1996;87(9):4011-3.
-
1996: Or R; Nagler A; Shpilberg O; Elad S; Naparstek E; Kapelushnik J; Cass Y; Gillis S; Chetrit A; Slavin S; Eldor A
Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients.
Transplantation 1996;61(7):1067-71.
-
1996: Slavin S; Naparstek E; Nagler A; Ackerstein A; Samuel S; Kapelushnik J; Brautbar C; Or R
Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.
Blood 1996;87(6):2195-204.
-
1996: Pugatsch T; Oppenheim A; Slavin S
Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT.
Bone marrow transplantation 1996;17(2):273-5.
-
1996: Chaushu G; Chaushu S; Slavin S; Or R; Garfunkel A A; Yefenof E
Salivary immunoglobulins in recipients of bone marrow grafts. III. A longitudinal follow-up of CMV specific antibodies.
Bone marrow transplantation 1996;17(2):237-41.
-
1996: Condiotti R; Slavin S; Nagler A
ASTA-Z 7557 impairs human natural killer (NK) cell activity.
Leukemia research 1996;20(2):169-74.
-
1996: Engelhard D; Elishoov H; Strauss N; Naparstek E; Nagler A; Simhon A; Raveh D; Slavin S; Or R
Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. A 5-year prospective study.
Transplantation 1996;61(3):430-4.
-
1996: Toren A; Or R; Kapelushnik J; Chividalli G; Aku M; Slavin S; Nagler A
Normalization of serum lactic dehydrogenase in beta-thalassemia patients following bone marrow transplantation.
American journal of hematology 1996;51(2):166-7.
-
1996: Condiotti R; Slavin S; Barak V; Nagler A
The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors.
Leukemia research 1996;20(1):57-63.
-
1996: Morecki S; Pugatsch T; Levi S; Moshel Y; Slavin S
Tumor-cell vaccination induces tumor dormancy in a murine model of B-cell leukemia/lymphoma (BCL1).
International journal of cancer. Journal international du cancer 1996;65(2):204-8.
-
1996: Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Clinical transplants 1996;():281-90.
-
1995: Varadi G; Or R; Rund D; Orbach H; Slavin S; Nagler A
Severe migratory polyarthritis following in vivo CAMPATH-1G.
Bone marrow transplantation 1995;16(6):843-5.
-
1995: Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Experimental hematology 1995;23(14):1553-62.
-
1995: Slavin S; Gross D; Weiss L
Prevention and treatment of type I diabetes in NOD mice by linomide.
Transplantation proceedings 1995;27(6):3240.
-
1995: Nagler A; Eldor A; Naparstek E; Mumcuoglu M; Slavin S; Deutsch V R
Ex vivo expansion of megakaryocyte precursors by preincubation of marrow allografts with interleukin-3 and granulocyte-macrophage colony-stimulating factor in vitro.
Experimental hematology 1995;23(12):1268-74.
-
1995: Nagler A; Or R; Nisman B; Kalickman I; Slavin S; Barak V
Elevated inflammatory cytokine levels in bone marrow graft rejection.
Transplantation 1995;60(9):943-8.
-
1995: Nagler A; Deutsch V R; Varadi G; Pick M; Eldor A; Slavin S
Recombinant human interleukin-6 accelerates in-vitro megakaryocytopoiesis and platelet recovery post autologous peripheral blood stem cell transplantation.
Leukemia & lymphoma 1995;19(3-4):343-9.
-
1995: Kapelushnik J; Or R; Filon D; Nagler A; Cividalli G; Aker M; Naparstek E; Slavin S; Oppenheim A
Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation.
Blood 1995;86(8):3241-6.
-
1995: Morecki S; Levi S; Puyesky Y; Slavin S
Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule.
Cancer immunology, immunotherapy : CII 1995;41(4):236-42.
-
1995: Toren A; Ackerstein A; Slavin S; Nagler A
Role of interleukin-2 in human hematological malignancies.
Medical oncology (Northwood, London, England) 1995;12(3):177-86.
-
1995: Weiss L; Reich S; Slavin S
The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
Bone marrow transplantation 1995;16(3):457-61.
-
1995: Delukina M; Kapelushnik Y; Or R; Naparstek E; Slavin S; Nagler A
Successful matched unrelated transplantation from a donor with idiopathic thrombocytopenic purpura (ITP).
Medical oncology (Northwood, London, England) 1995;12(2):125-7.
-
1995: Nagler A; Segal V; Slavin S; Levi-Schaffer F
Ketotifen therapy in chronic graft-versus-host disease (cGVHD): effect on mast cells and fibroblasts.
Clinical and experimental immunology 1995;100(3):529-35.
-
1995: Karussis D M; Vourka-Karussis U; Lehmann D; Abramsky O; Ben-Nun A; Slavin S
Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT).
Clinical and experimental immunology 1995;100(1):111-7.
-
1995: Vourka-Karussis U; Karussis D; Ackerstein A; Slavin S
Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice.
Experimental hematology 1995;23(3):196-201.
-
1995: Nagler A; Ilan Y; Adler R; Or R; Naparstek E; Shouval D; Slavin S
Successful immunization of autologous bone marrow transplantation recipients against hepatitis B virus by active vaccination.
Bone marrow transplantation 1995;15(3):475-8.
-
1995: Chaushu G; Itzkovitz-Chaushu S; Yefenof E; Slavin S; Or R; Garfunkel A A
A longitudinal follow-up of salivary secretion in bone marrow transplant patients.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 1995;79(2):164-9.
-
1995: Karussis D M; Lehmann D; Slavin S; Kalland T; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Abramsky O
Immunomodulation of autoimmunity by linomide.
Israel journal of medical sciences 1995;31(1):38-41.
-
1995: Deutsch V R; Olson T A; Nagler A; Slavin S; Levine R F; Eldor A
The response of cord blood megakaryocyte progenitors to IL-3, IL-6 and aplastic canine serum varies with gestational age.
British journal of haematology 1995;89(1):8-16.
-
1995: Abdul-Hai A; Lorberboum-Gliski H; Mechushtan A; Weiss L; Slavin S; Or R
Involvement of interleukin-2 in immunologic reconstitution following bone marrow transplantation in mice.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(1):95-101.
-
1994: Gross D J; Sidi H; Weiss L; Kalland T; Rosenmann E; Slavin S
Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug.
Diabetologia 1994;37(12):1195-201.
-
1994: Chaushu S; Chaushu G; Garfunkel A; Slavin S; Or R; Yefenof E
Salivary immunoglobulins in recipients of bone marrow grafts. II. Transient secretion of donor-derived salivary IgA following transplantation of T cell-depleted bone marrow.
Bone marrow transplantation 1994;14(6):925-8.
-
1994: Chaushu S; Chaushu G; Garfunkel A A; Slavin S; Or R; Yefenof E
Salivary immunoglobulins in recipients of bone marrow grafts. I. A longitudinal follow-up.
Bone marrow transplantation 1994;14(6):871-6.
-
1994: Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(6):2562-7.
-
1994: Amiel A; Yarkoni S; Slavin S; Or R; Lorberboum-Galski H; Fejgin M; Nagler A
Detection of minimal residual disease state in chronic myelogenous leukemia patients using fluorescence in situ hybridization.
Cancer genetics and cytogenetics 1994;76(1):59-64.
-
1994: Ilan Y; Nagler A; Shouval D; Ackerstein A; Or R; Kapelushnik J; Adler R; Slavin S
Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipient following treatment with peripheral blood lymphocytes from immunized donors.
Clinical and experimental immunology 1994;97(2):299-302.
-
1994: Weiss L; Slavin S
Effect of total lymphoid irradiation on natural killer cells and cytotoxic and primed T lymphocytes.
Israel journal of medical sciences 1994;30(4):253-9.
-
1994: Nagler A; Slavin S; Yarkoni S; Fejgin M; Amiel A
Detection of minimal residual disease after sex-mismatch bone marrow transplantation in chronic myelogenous leukemia by fluorescence in situ hybridization.
Cancer genetics and cytogenetics 1994;73(2):130-3.
-
1994: Givon T; Revel M; Slavin S
Potential use of interleukin-6 in bone marrow transplantation: effects of recombinant human interleukin-6 after syngeneic and semiallogeneic bone marrow transplantation in mice.
Blood 1994;83(6):1690-7.
-
1994: Or R; Mehta J; Kapelushnik J; Aker M; Naparstek E; Nagler A; Cividalli G; Slavin S
Total lymphoid irradiation, anti-lymphocyte globulin and Campath 1-G for immunosuppression prior to bone marrow transplantation for aplastic anemia after repeated graft rejection.
Bone marrow transplantation 1994;13(1):97-9.
-
1994: Weiss L; Slavin G; Reich S; Sidi H; Slavin S
Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).
Bone marrow transplantation 1994;13(1):27-30.
-
1994: Nagler A; Ackerstein A; Barak V; Slavin S
Treatment of chronic myelogenous leukemia with recombinant human interleukin-2 and interferon-alpha 2a.
Journal of hematotherapy 1994;3(1):75-82.
-
1993: Slavin S; Sidi H; Weiss L; Rosenman E; Kalland T; Gross D
Linomide, a new treatment for autoimmune diseases: the potential in type 1 diabetes.
Diabetes/metabolism reviews 1993;9(4):311-5.
-
1993: Cohen P; Vourka-Karussis U; Weiss L; Slavin S
Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(9):4803-10.
-
1993: Karussis D M; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Ben-Nun A; Kalland T; Abramsky O
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide.
Annals of neurology 1993;34(5):654-60.
-
1993: Pugatsch T; Weiss L; Slavin S
Minimal residual disease in murine B-cell leukemia (BCL1) detected by PCR.
Leukemia research 1993;17(11):999-1002.
-
1993: Deutsch V R; Nagler A; Slavin S; Condiotti R; Levine R F; Eldor A
Effect of bone marrow T lymphocytes treated with CAMPATH 1G on megakaryocyte colony formation.
Experimental hematology 1993;21(11):1427-35.
-
1993: Drakos P E; Nagler A; Or R; Naparstek E; Kapelushnik J; Engelhard D; Rahav G; Ne'emean D; Slavin S
Invasive fungal sinusitis in patients undergoing bone marrow transplantation.
Bone marrow transplantation 1993;12(3):203-8.
-
1993: Naparstek E; Slavin S; Weiss L; Sidi H; Ohana M; Reich S; Vlodavsky I; Cohen I R; Naparstek Y
Low-dose heparin inhibits acute graft versus host disease in mice.
Bone marrow transplantation 1993;12(3):185-9.
-
1993: Loewenthal E; Weiss L; Samuel S; Or R; Slavin S
Optimization of conditioning therapy for leukemia prior to BMT. I. Optimal synergism between cyclophosphamide and total body irradiation for eradication of murine B cell leukemia (BCL1).
Bone marrow transplantation 1993;12(2):109-13.
-
1993: Weiss L; Stern S; Reich S; Slavin S
Effect of recombinant human manganese superoxide dismutase on radiosensitivity of murine B cell leukemia (BCL1) cells.
Leukemia & lymphoma 1993;10(6):477-81.
-
1993: Bishara A; Kedar E; Leshem B; Slavin S; Cohen I; Brautbar C
A 2-day MLR procedure for marrow donor selection for allogeneic bone marrow transplantation.
European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics 1993;20(4):289-92.
-
1993: Ilan Y; Nagler A; Adler R; Naparstek E; Or R; Slavin S; Brautbar C; Shouval D
Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation.
Hepatology (Baltimore, Md.) 1993;18(2):246-52.
-
1993: Karussis D M; Vourka-Karussis U; Lehmann D; Ovadia H; Mizrachi-Koll R; Ben-Nun A; Abramsky O; Slavin S
Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.
The Journal of clinical investigation 1993;92(2):765-72.
-
1993: Karussis D M; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Kalland T; Abramsky O
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
Proceedings of the National Academy of Sciences of the United States of America 1993;90(14):6400-4.
-
1993: Slavin S
Treatment of life-threatening autoimmune diseases with myeloablative doses of immunosuppressive agents: experimental background and rationale for ABMT.
Bone marrow transplantation 1993;12(1):85-8.
-
1993: Kapelushnik J; Nagler A; Or R; Naparstek E; Cividalli G; Aker M; Mehta J; Mumcuoglu M; Slavin S
Autologous bone marrow transplantation for stage IV neuroblastoma: the role of soybean agglutinin purging.
Transplantation proceedings 1993;25(3):2375-6.
-
1993: Ilan Y; Nagler A; Adler R; Tur-Kaspa R; Slavin S; Shouval D
Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor.
Gastroenterology 1993;104(6):1818-21.
-
1993: Morecki S; Nagler A; Puyesky Y; Nabet C; Condiotti R; Pick M; Gan S; Slavin S
Effect of various cytokine combinations on induction of non-MHC-restricted cytotoxicity.
Lymphokine and cytokine research 1993;12(3):159-65.
-
1993: Engelhard D; Naparstek E; Or R; Nagler A; Jacobs J; Shahar M B; Hardan I; Baciu H; Raveh D; Slavin S
Ganciclovir for the treatment of disseminated CMV disease without pneumonia in allogeneic T-lymphocyte depleted bone marrow transplantation.
Leukemia & lymphoma 1993;10(1-2):143-6.
-
1993: Slavin S; Karussis D; Weiss L; Vourka-Karussis U; Abramsky O
Immunohematopoietic reconstitution by allogeneic and autologous bone marrow grafts as a means for induction of specific unresponsiveness to donor-specific allografts and modified self in autoimmune disorders.
Transplantation proceedings 1993;25(1 Pt 2):1274-5.
-
1993: Nagler A; Mumcuoglu M; Naparstek E; Or R; Gan S; Slavin S
Normal hematopoietic reconstitution following ASTA-Z 7557-purged grafts in the absence of in vitro CFU-GM colony growth.
Leukemia research 1993;17(1):61-7.
-
1993: Naparstek E; Ohana M; Greenberger J S; Slavin S
Continuous intravenous administration of rmGM-CSF enhances immune as well as hematopoietic reconstitution following syngeneic bone marrow transplantation in mice.
Experimental hematology 1993;21(1):131-7.
-
1993: Slavin S; Weiss L; Ackerstein A; Vourka-Karussis U; Morecki S; Or R; Nagler A; Kapelushnik J; Delukina M; Drakos P
Prevention and treatment of relapse by bone marrow transplantation.
Bone marrow transplantation 1993;12 Suppl 3():S54-6.
-
1992: Stark J; Weiss L; Slavin S
Radiosensitivity and responsiveness to recombinant interleukin-2 of effector cells of graft vs. host disease and mixed lymphocyte reaction in mice.
Israel journal of medical sciences 1992;28(11):767-72.
-
1992: Slavin S; Or R; Kapelushnik Y; Drakos P; Ackerstein A; Vourka-Karussis U; Weiss L; Nagler A
Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT).
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1992;6 Suppl 4():164-6.
-
1992: Or R; Mehta J; Naparstek E; Okon E; Cividalli G; Slavin S
Successful T cell-depleted allogeneic bone marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas.
Bone marrow transplantation 1992;10(4):381-2.
-
1992: Samuel S; Nagler A; Or R; Slavin S
Effects of interleukin 2 on engraftment following autologous bone marrow transplantation (ABMT) in dogs.
Leukemia research 1992;16(10):967-72.
-
1992: Naparstek E; Hardan Y; Ben-Shahar M; Nagler A; Or R; Mumcuoglu M; Weiss L; Samuel S; Slavin S
Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor.
Blood 1992;80(7):1673-8.
-
1992: Drakos P E; Nagler A; Or R; Gillis S; Slavin S; Eldor A
Low molecular weight heparin for Hickman catheter--induced thrombosis in thrombocytopenic patients undergoing bone marrow transplantation.
Cancer 1992;70(7):1895-8.
-
1992: Karussis D M; Slavin S; Ben-Nun A; Ovadia H; Vourka-Karussis U; Lehmann D; Mizrachi-Kol R; Abramsky O
Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation.
Journal of neuroimmunology 1992;39(3):201-10.
-
1992: Bieder A; Weiss L; Slavin S
The role of recombinant cytokines and other immunomodulators on engraftment following allogeneic bone marrow transplantation in mice.
Bone marrow transplantation 1992;9(6):421-6.
-
1992: Karussis D M; Slavin S; Lehmann D; Mizrachi-Koll R; Abramsky O; Ben-Nun A
Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation.
Journal of immunology (Baltimore, Md. : 1950) 1992;148(6):1693-8.
-
1992: Nagler A; Pavel L; Naparstek E; Muggia-Sullam M; Slavin S
Typhlitis occurring in autologous bone marrow transplantation.
Bone marrow transplantation 1992;9(1):63-4.
-
1992: Breuer R; Tochner Z; Conner M W; Nimrod A; Gorecki M; Or R; Slavin S
Superoxide dismutase inhibits radiation-induced lung injury in hamsters.
Lung 1992;170(1):19-29.
-
1992: Slavin S; Ackerstein A; Weiss L; Nagler A; Or R; Naparstek E
Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines.
Cancer investigation 1992;10(3):221-7.
-
1992: Slavin S; Naparstek E; Ziegler M; Lewin A
Clinical application of intrauterine bone marrow transplantation for treatment of genetic diseases--feasibility studies.
Bone marrow transplantation 1992;9 Suppl 1():189-90.
-
1992: Morecki S; Revel-Vilk S; Nabet C; Pick M; Ackerstein A; Nagler A; Naparstek E; Ben Shahar M; Slavin S
Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.
Cancer immunology, immunotherapy : CII 1992;35(6):401-11.
-
1991: Engelhard D; Handsher R; Naparstek E; Hardan I; Strauss N; Aker M; Or R; Baciu H; Slavin S
Immune response to polio vaccination in bone marrow transplant recipients.
Bone marrow transplantation 1991;8(4):295-300.
-
1991: Ackerstein A; Kedar E; Slavin S
Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders.
Blood 1991;78(5):1212-5.
-
1991: Slavin S; Ackerstein A; Vourka-Karussis U; Nagler A; Or R; Naparstek E; Weiss L
Control of relapse due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation.
Baillière's clinical haematology 1991;4(3):715-25.
-
1991: Or R; Naparstek E; Mani N; Slavin S
Treatment of pure red-cell aplasia following major ABO-mismatched T-cell-depleted bone marrow transplantation. Two case reports with successful response to plasmapheresis.
Transplant international : official journal of the European Society for Organ Transplantation 1991;4(2):99-102.
-
1991: Gomez S; Nagler A; Naparstek E; Slavin S
Transient elevation of serum lactic dehydrogenase following autologous bone marrow transplantation.
Bone marrow transplantation 1991;7(6):487-8.
-
1991: Morecki S; Nabet C; Ackerstein A; Schlesinger M; Slavin S
The effect of in vitro T lymphocyte depletion on generation of IL2-activated cytotoxic cells.
Bone marrow transplantation 1991;7(4):269-73.
-
1991: Mumcuoglu M; Zakay-Rones Z; Weiss L; Slavin S
The effect of total or partial T lymphocyte depletion on susceptibility to influenza virus infection and development of antiviral immunity in lethally irradiated mice reconstituted with immune syngeneic bone marrow grafts.
Bone marrow transplantation 1991;7(3):217-20.
-
1991: Slavin S; Ackerstein A; Kedar E; Reich S; Gomez S; Naparstek E; Nagler A; Or R; Weiss L
Induction of cell-mediated IL-2-activated antitumor responses in conjunction with autologous and allogeneic bone marrow transplantation.
Transplantation proceedings 1991;23(1 Pt 1):802-3.
-
1991: Gorecki M; Beck Y; Hartman J R; Fischer M; Weiss L; Tochner Z; Slavin S; Nimrod A
Recombinant human superoxide dismutases: production and potential therapeutical uses.
Free radical research communications 1991;12-13 Pt 1():401-10.
-
1990: Eid A; Morecki S; Slavin S
The use of parabiosis for investigating the mechanism of transplantation tolerance in bone marrow chimeras induced by total lymphoid irradiation.
Transplant international : official journal of the European Society for Organ Transplantation 1990;3(3):141-5.
-
1990: Weiss L; Reich S; Slavin S
Effect of cyclosporine A and methylprednisolone on the graft-versus-leukemia effects across major histocompatibility barriers in mice following allogeneic bone marrow transplantation.
Bone marrow transplantation 1990;6(4):229-33.
-
1990: Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Bone marrow transplantation 1990;6(3):155-61.
-
1990: Slavin S; Ackerstein A; Kedar E; Weiss L
IL-2 activated cell-mediated immunotherapy: control of minimal residual disease in malignant disorders by allogeneic lymphocytes and IL-2.
Bone marrow transplantation 1990;6 Suppl 1():86-90.
-
1990: Mumcuoglu M; Naparstek E; Slavin S
The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
Bone marrow transplantation 1990;5(3):153-8.
-
1990: Eckerstein A; Slavin S; Weiss L; Naparstek E
Immunotherapy in conjunction with autologous bone marrow transplantation.
Bone marrow transplantation 1990;5 Suppl 1():38.
-
1990: Mumcuoglu M; Favrot M; Slavin S
Lectin-binding properties of Burkitt's lymphoma cell lines: application to bone marrow purging.
Experimental hematology 1990;18(1):55-60.
-
1990: Weshler Z; Breuer R; Or R; Naparstek E; Pfeffer M R; Lowental E; Slavin S
Interstitial pneumonitis after total body irradiation: effect of partial lung shielding.
British journal of haematology 1990;74(1):61-4.
-
1990: Weiss L; Weigensberg M; Morecki S; Bar S; Cobbold S; Waldmann H; Slavin S
Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia.
Cancer immunology, immunotherapy : CII 1990;31(4):236-42.
-
1990: Slavin S; Eckerstein A; Hardan I; Ben Shahar M; Or R; Naparstek E; Weiss L
Toward improvement of therapeutic strategies in leukemia by amplification of the immune responses against leukemia.
Haematology and blood transfusion 1990;33():36-40.
-
1989: Slavin S; Mumcuoglu M; Landesberg-Weisz A; Kedar E
The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z).
Bone marrow transplantation 1989;4(5):459-64.
-
1989: Morecki S; Slavin S; Ben-Sasson S A
Selective abrogation of alloreactivity via priming in the presence of aphidicolin, a specific inhibitor of DNA polymerase.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(3):838-43.
-
1989: Mumcuoglu M; Weiss L; Spivak J; Slavin S
Differential killing of murine B-cell leukemia (BCL1) by photosensitization with merocyanine 540: implications for autologous bone marrow transplantation.
Bone marrow transplantation 1989;4(2):143-6.
-
1989: Slavin S; Naparstek E; Aker M; Cividalli G; Engelhard D; Hardan Y; Bromiker R; Brautbar C; Weshler Z; Or R
The use of total lymphoid irradiation (TLI) for prevention of rejection of T-lymphocyte depleted bone marrow allografts in non-malignant hematological disorders.
Transplantation proceedings 1989;21(1 Pt 3):3053-4.
-
1988: Tochner Z; Slavin S
Immune modulation by ionized irradiation.
Current opinion in immunology 1988;1(2):261-8.
-
1988: Breuer R; Or R; Lijovetzky G; Naparstek E; Engelhard D; Lafair J; Weshler Z; Slavin S
Interstitial pneumonitis in T cell-depleted bone marrow transplantation.
Bone marrow transplantation 1988;3(6):625-30.
-
1988: Morecki S; Slavin S
Combination of magnetic and chemocytotoxic cancer cell depletion for autologous bone marrow transplantation.
Israel journal of medical sciences 1988;24(9-10):488-93.
-
1988: Morecki S; Margel S; Slavin S
Removal of breast cancer cells by soybean agglutinin in an experimental model for purging human marrow.
Cancer research 1988;48(16):4573-7.
-
1988: Eid A; Morecki S; Slavin S
Induction of transplantation tolerance by intraportal injection of allogeneic bone marrow cells. Possible implications for intrauterine bone marrow transplantation across major histocompatibility barriers.
Transplant international : official journal of the European Society for Organ Transplantation 1988;1(2):109-12.
-
1988: Kedar E; Tsuberi B Z; Landesberg A; Anafi M; Leshem B; Gillis S; Urdal D L; Slavin S
In vitro and in vivo cytokine-induced facilitation of immunohematopoietic reconstitution in mice undergoing bone marrow transplantation.
Bone marrow transplantation 1988;3(4):297-314.
-
1988: Slavin S
Use of total lymphoid irradiation (TLI) for the treatment of autoimmune disorders.
Israel journal of medical sciences 1988;24(7):375-8.
-
1988: Yehuda A B; Or R; Naparstek E; Slavin S; Polliack A
T-cell depleted bone marrow transplantation for plasma cell myeloma. Report of a case and review of the results of BMT for myeloma.
Blut 1988;56(5):229-31.
-
1988: Weiss L; Bullorsky E; Ashkenazi Y J; Slavin S
Optimal time interval between myeloablative whole body irradiation and reconstitution with syngeneic bone marrow graft.
Bone marrow transplantation 1988;3(3):207-10.
-
1988: Engelhard D; Morag A; Or R; Naparstek E; Cividalli G; Ruchlemer R; Aker M; Maayan S; Slavin S
Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts.
Israel journal of medical sciences 1988;24(3):145-50.
-
1988: Kedar E; Or R; Naparstek E; Zeira E; Slavin S
Preliminary characterization of functional residual host-type T lymphocytes following conditioning for allogeneic HLA-matched bone marrow transplantation (BMT).
Bone marrow transplantation 1988;3(2):129-40.
-
1988: Slavin S; Eckerstein A; Weiss L
Adoptive immunotherapy in conjunction with bone marrow transplantation--amplification of natural host defence mechanisms against cancer by recombinant IL-2.
Natural immunity and cell growth regulation 1988;7(3):180-4.
-
1987: Gazitt Y; Or R; Mumcuoglu M; Slavin S
Monoclonal rat anti-human lymphocyte antibody Campath-1 binds to T and B lymphocytes but effectively lyses only T cells.
Bone marrow transplantation 1987;2(4):427-33.
-
1987: Mumcuoglu M; Zakay-Rones Z; Parag G; Weiss L; Slavin S
The effect of T lymphocyte depletion on susceptibility to influenza virus infection and development of anti-viral immunity in lethally irradiated mice reconstituted with syngeneic bone marrow grafts.
Bone marrow transplantation 1987;2(4):403-12.
-
1987: Leshem B; Lebendiker Z; Weiss L; Slavin S; Kedar E
Suppressor T cells in allogeneic bone marrow chimeras.
Bone marrow transplantation 1987;2(2):123-32.
-
1987: Leshem B; Tsuberi B Z; Lebendiker Z; Anafi-Ayalon M; Shalit M; Weiss L; Slavin S; Kedar E
Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens.
Transplantation 1987;43(6):814-7.
-
1987: Morecki S; Pavlotzky F; Margel S; Slavin S
Purging breast cancer cells in preparation for autologous bone marrow transplantation.
Bone marrow transplantation 1987;1(4):357-63.
-
1987: Tsuberi B; Slavin S; Kedar E; Leshem B
Transfer of B memory cells to a T-dependent antigen in murine bone marrow transplantation.
Transplantation proceedings 1987;19(1 Pt 3):2747-9.
-
1987: Slavin S; Or R; Naparstek E; Weiss L; Mumcuoglu M; Weshler Z; Brautbar H; Cividalli G; Glikson M; Hale G
Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
Transplantation proceedings 1987;19(1 Pt 3):2614-5.
-
1986: Slavin S; Morecki S; Weigensberg M; Bar S; Weiss L
Functional clonal deletion versus suppressor cell-induced transplantation tolerance in chimeras prepared with a short course of total-lymphoid irradiation.
Transplantation 1986;41(6):680-7.
-
1986: Slavin S; Rachmilewitz E A
Bone marrow transplantation in thalassaemia.
Bone marrow transplantation 1986;1(1):11-5.
-
1985: Morecki S; Leshem B; Weigensberg M; Bar S; Slavin S
Functional clonal deletion versus active suppression in transplantation tolerance induced by total-lymphoid irradiation.
Transplantation 1985;40(2):201-10.
-
1985: Morecki S; Weigensberg M; Slavin S
Lectin separation of nonlymphoid suppressor cells induced by total lymphoid irradiation.
European journal of immunology 1985;15(2):138-48.
-
1985: Slavin S; Or R; Weshler Z; Fuks Z; Morecki S; Weigensberg M; Bar S; Weiss L
The use of total lymphoid irradiation for allogeneic bone marrow transplantation in animals and man.
Survey of immunologic research 1985;4(3):238-52.
-
1985: Slavin S; Weigensberg M; Bar S; Weiss L; Morecki S
The role of suppressor T lymphocytes in the maintenance of tolerance to alloantigens in bone marrow chimeras prepared with total lymphoid irradiation (TLI).
Advances in experimental medicine and biology 1985;186():503-9.
-
1984: Weigensberg M; Morecki S; Weiss L; Fuks Z; Slavin S
Suppression of cell-mediated immune responses after total lymphoid irradiation (TLI). I. Characterization of suppressor cells of the mixed lymphocyte reaction.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(2):971-8.
-
1984: Morecki S; Slavin S; Weiss L; Weigensberg M; Friedman A; Kotler M
Demonstration and characterization of virus released by murine B cell leukemia cells (BCL1).
Leukemia research 1984;8(5):821-32.
Sign-in to see more
